Immunome (IMNM) Other Operating Expenses (2023 - 2025)

Immunome has reported Other Operating Expenses for 3 years, with the latest figure at $10.0 million in Q4 2025.

• For the quarter ending Q4 2025, Other Operating Expenses fell 63.47% year-over-year to $10.0 million; the trailing twelve-month figure through Mar 2026 stood at $10.0 million (down 75.24% YoY), and the FY2025 full-year result was $10.0 million, down 93.44% from the prior year.
• Other Operating Expenses for Q4 2025 stood at $10.0 million, down from $27.4 million in the prior quarter.
• The five-year high for Other Operating Expenses was $112.0 million in Q1 2024, with the low at $6.3 million in Q2 2024.
• Historically, Other Operating Expenses has averaged $40.5 million across 3 years, with a median of $18.7 million in 2024.
• Annual changes were most pronounced in 2024 — Other Operating Expenses plunged 66.12% — and 2025, when it tumbled 63.47%.
• Immunome's Other Operating Expenses stood at $80.8 million in 2023, then sank by 66.12% to $27.4 million in 2024, then plunged by 63.47% to $10.0 million in 2025.
• The last three Other Operating Expenses figures came in at $10.0 million (Q4 2025), $27.4 million (Q4 2024), and $6.7 million (Q3 2024), per Business Quant data.